Application Nr Approved Date Route Status External Links
ANDA202931 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Frovatriptan Succinate Tablets Are Indicated For The Acute Treatment Of Migraine With Or Without Aura In Adults. Limitations Of Use: • Use Only If A Clear Diagnosis Of Migraine Has Been Established. If A Patient Has No Response For The First Migraine Attack Treated With Frovatriptan Succinate Tablets, Reconsider The Diagnosis Of Migraine Before Frovatriptan Succinate Tablets Are Administered To Treat Any Subsequent Attacks. • Frovatriptan Succinate Tablets Are Not Indicated For The Prevention Of Migraine Attacks. • Safety And Effectiveness Of Frovatriptan Succinate Tablets Have Not Been Established For Cluster Headache. Frovatriptan Succinate Tablets Are A Serotonin (5-Ht 1b/1d ) Receptor Agonist (Triptan) Indicated For The Acute Treatment Of Migraine With Or Without Aura In Adults ( 1 ) Limitations Of Use • Use Only After A Clear Diagnosis Of Migraine Has Been Established ( 1 ) • Not Indicated For The Prophylactic Therapy Of Migraine ( 1 ) • Not Indicated For The Treatment Of Cluster Headache ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Frovatriptan Succinate FROVATRIPTAN SUCCINATE ZINC895030

Comments